Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Meng-Meng Ji, Siyuan Chen, Yige Shen, Li Wang, Shu Cheng, Pengpeng Xu, Wei Tang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2025-3732

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Yaohui Huang, Siyi Chen, Shu Cheng, Pengpeng Xu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 5382.

https://doi.org/10.1182/blood-2025-5382

Published: 2025

Journal Articles

Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma （zana）: A prospective, single-arm study

Zhizhou Xia, Qifan Xu, Shu Cheng, Pengpeng Xu, Wei Li Zhao, Wang Li

Blood (2025) 146 (Supplement 1): 60.

https://doi.org/10.1182/blood-2025-60

Published: 2025

Journal Articles

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Li Wang, Zhong Zheng, Ruichi Li, Pengpeng Xu, Shu Cheng, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7123.

https://doi.org/10.1182/blood-2025-7123

Published: 2025

Journal Articles

Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)

Li Wang, Jianzhen Shen, Yaohui Huang, Jing Bao, Lin Shen, Pengpeng Xu, Shu Cheng, Hongming Zhu, Weili Zhao

Blood (2025) 146 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2025-3599

Published: 2025

Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Blood (2025) 146 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2025-3689

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

The Impact of Gut Microbiota Diversity on Follicular Lymphoma: Insights into Disease Progression and Therapy

Li Zhang, Bintao Xie, Jiakuan Zhou, Han Lin, Jun Meng, Jianbiao Wang, Haiyang Lu, Lina Zhang, Xiaohua Chen, Xiaohui Zhou, Hao Liu, Pengpeng Xu

Blood (2024) 144 (Supplement 1): 6275.

https://doi.org/10.1182/blood-2024-205472

Published: 2024

Journal Articles

Indole-3 Propionic Acid Deficiency and Gut Microbiota Imbalance in Follicular Lymphoma: Implications for Disease Progression and Therapeutic Potential

Li Zhang, Bintao Xie, Jiakuan Zhou, Han Lin, Haiyang Lu, Jun Meng, Jianbiao Wang, Pengpeng Xu, Lina Zhang, Xiaohua Chen, Xiaohui Zhou, Hao Liu

Blood (2024) 144 (Supplement 1): 6252.

https://doi.org/10.1182/blood-2024-205708

Published: 2024

Journal Articles

Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Shu Cheng, Li Wang, Pengpeng Xu, Muchen Zhang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4502.3.

https://doi.org/10.1182/blood-2024-204749

Published: 2024

Journal Articles

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Yue Wang, Xue Wang, Xinyun Huang, Ying Qian, Rongji Mu, Qing Shi, Di Fu, Hongmei Yi, Bin-Shen Ou-Yang, Zhuo Han Li, Shu Cheng, Wang Li, Ning Wen, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2024-206537

Published: 2024

Journal Articles

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

Tianyuan Xu, Nan Wang, Rui Sun, Ruichi Li, Di Fu, Yan Zhao, Pengpeng Xu, Shu Cheng, Li Wang, Wei Tang, Zhong Zheng, Weili Zhao

Blood (2024) 144 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2024-204775

Published: 2024

Journal Articles

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4822.

https://doi.org/10.1182/blood-2024-198296

Published: 2024

Journal Articles

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Siyuan Chen, Li Wang, Pengpeng Xu, Shu Cheng, Wei Tang, Wen Wu, Mengmeng Ji, Zhong Zheng, Zixun Yan, Lingshuang Sheng, Yige Shen, Weili Zhao

Blood (2024) 144 (Supplement 1): 6553.

https://doi.org/10.1182/blood-2024-203842

Published: 2024

Journal Articles

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Yuqing Wang, Shuo Wang, Hongmei Yi, Yue Wang, Haimin Xu, Shuang Tian, Yan Dong, Jing Zhao, Di Fu, Rongji Mu, Shuye Wang, Li Wang, Pengpeng Xu, Wei Li Zhao

Blood (2024) 144 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2024-202864

Published: 2024

Journal Articles

Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL

Yige Shen, Yiwen Cao, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao

Blood (2023) 142 (Supplement 1): 3091.

https://doi.org/10.1182/blood-2023-182603

Published: 2023

Journal Articles

Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma

Yige Shen, Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao

Blood (2023) 142 (Supplement 1): 4488.

https://doi.org/10.1182/blood-2023-188042

Published: 2023

Journal Articles

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Pengpeng Xu, Wang Li, Shu Cheng, Wei Li Zhao

Blood (2023) 142 (Supplement 1): 6229.

https://doi.org/10.1182/blood-2023-186087

Published: 2023

Journal Articles

Selinexor in Combination with Salvage Regimen for Refractory Peripheral T-Cell Lymphoma (PTCL) Patients

Li Wang, Mingci CAI, Yaohui Huang, Pengpeng Xu, Shu Chen, Weili Zhao

Blood (2023) 142 (Supplement 1): 6211.

https://doi.org/10.1182/blood-2023-183040

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma （zana）: A prospective, single-arm study

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

The Impact of Gut Microbiota Diversity on Follicular Lymphoma: Insights into Disease Progression and Therapy

Indole-3 Propionic Acid Deficiency and Gut Microbiota Imbalance in Follicular Lymphoma: Implications for Disease Progression and Therapeutic Potential

Integration of Deep Learning in Baseline PET/CT and Multi-Omics Data for Prognostic Modeling in Diffuse Large B-Cell Lymphoma: The Clinicalpet Lymphplex Model

Integration of Gene Mutations in Risk Prognostication for Watch-and-Wait Follicular Lymphoma Patients Initiating First-Line Treatment

LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Auto-HSCT Vs CAR-T Cell Therapy for Paients with Relapsed/Refractory DLBCL in Partial Remission with Deauville Score of 4 or 5 after Salvage Chemotherapy

Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology

Novel Targeted Agents in Combination with R-ICE (R-ICE-X) Based on Genotyping in Relapsed/Refractory DLBCL

Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma

Preliminary Results from a Phase I/II Study of Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE)

Selinexor in Combination with Salvage Regimen for Refractory Peripheral T-Cell Lymphoma (PTCL) Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only